FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4365139813> ?p ?o ?g. }

• W4365139813 endingPage "519" @default.
• W4365139813 startingPage "516" @default.
• W4365139813 abstract "Vericiguat reduced the risk of cardiovascular death (CVD) or hospitalization for heart failure (HF) in patients with worsening HF and reduced left ventricular ejection fraction (LVEF).The authors assessed the association of LVEF with biomarker levels, risk of outcome, and whether the effect of vericiguat was homogeneous across LVEF in the VICTORIA (Vericiguat Global Study in Subjects with Heart Failure With Reduced Ejection Fraction) trial.Patients were grouped by LVEF tertiles (≤24%, 25%-33%, and >33%). Patient characteristics, clinical outcomes, and efficacy and safety of vericiguat were examined by tertile. Prespecified biomarkers including N-terminal pro–B-type natriuretic peptide, cardiac troponin T, growth differentiation factor 15, interleukin 6, high-sensitivity C-reactive protein, and cystatin C were examined.The mean LVEF was 29% ± 8% (range: 5%-45%). A pattern of higher N-terminal pro–B-type natriuretic peptide, high-sensitivity C-reactive protein, and interleukin 6 was evident in patients in the lowest LVEF tertile vs the other tertiles. Patients with lower LVEF experienced higher rates of the composite outcome (41.7%, 36.3%, and 33.4% for LVEF ≤24, 25-33, and >33; P < 0.001). There was no significant treatment effect heterogeneity of vericiguat across LVEF groups (adjusted HR from lowest to highest tertiles: 0.79 [95% CI: 0.68-0.94]; 0.95 [95% CI: 0.82-1.11]; 0.94 [95% CI: 0.79-1.11]; P for interaction = 0.222), although the HR was numerically lower in the lowest tertile. There was also no heterogeneity of effect for CVD and HF hospitalization individually (P interaction for CVD = 0.964; HF hospitalization = 0.438). Discontinuation of treatment because of adverse events, symptomatic hypotension, or syncope was consistent across the range of LVEF.Patients with lower LVEF had a distinctive biomarker profile and a higher risk for adverse clinical outcomes vs those with a higher LVEF. There was no significant interaction for the benefit of vericiguat across LVEF tertiles, although the largest signal for benefit in both the primary outcome and HF hospitalizations was noted in tertile 1 (LVEF ≤24%). (Vericiguat Global Study in Subjects with Heart Failure With Reduced Ejection Fraction [VICTORIA]; NCT02861534)" @default.
• W4365139813 created "2023-04-13" @default.
• W4365139813 creator A5009114857 @default.
• W4365139813 creator A5068868001 @default.
• W4365139813 creator A5079556755 @default.
• W4365139813 date "2023-05-01" @default.
• W4365139813 modified "2023-09-29" @default.
• W4365139813 title "How to Make the Transplantation Allocation System Better" @default.
• W4365139813 cites W1506336777 @default.
• W4365139813 cites W2985308186 @default.
• W4365139813 cites W3007805048 @default.
• W4365139813 cites W3015695051 @default.
• W4365139813 cites W3024498834 @default.
• W4365139813 cites W3033884323 @default.
• W4365139813 cites W4220791766 @default.
• W4365139813 doi "https://doi.org/10.1016/j.jchf.2022.11.029" @default.
• W4365139813 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37137658" @default.
• W4365139813 hasPublicationYear "2023" @default.
• W4365139813 type Work @default.
• W4365139813 citedByCount "0" @default.
• W4365139813 crossrefType "journal-article" @default.
• W4365139813 hasAuthorship W4365139813A5009114857 @default.
• W4365139813 hasAuthorship W4365139813A5068868001 @default.
• W4365139813 hasAuthorship W4365139813A5079556755 @default.
• W4365139813 hasConcept C126322002 @default.
• W4365139813 hasConcept C164705383 @default.
• W4365139813 hasConcept C2775915353 @default.
• W4365139813 hasConcept C2778198053 @default.
• W4365139813 hasConcept C2779548226 @default.
• W4365139813 hasConcept C2780306776 @default.
• W4365139813 hasConcept C36036425 @default.
• W4365139813 hasConcept C500558357 @default.
• W4365139813 hasConcept C71924100 @default.
• W4365139813 hasConcept C78085059 @default.
• W4365139813 hasConceptScore W4365139813C126322002 @default.
• W4365139813 hasConceptScore W4365139813C164705383 @default.
• W4365139813 hasConceptScore W4365139813C2775915353 @default.
• W4365139813 hasConceptScore W4365139813C2778198053 @default.
• W4365139813 hasConceptScore W4365139813C2779548226 @default.
• W4365139813 hasConceptScore W4365139813C2780306776 @default.
• W4365139813 hasConceptScore W4365139813C36036425 @default.
• W4365139813 hasConceptScore W4365139813C500558357 @default.
• W4365139813 hasConceptScore W4365139813C71924100 @default.
• W4365139813 hasConceptScore W4365139813C78085059 @default.
• W4365139813 hasIssue "5" @default.
• W4365139813 hasLocation W43651398131 @default.
• W4365139813 hasLocation W43651398132 @default.
• W4365139813 hasOpenAccess W4365139813 @default.
• W4365139813 hasPrimaryLocation W43651398131 @default.
• W4365139813 hasRelatedWork W2051712573 @default.
• W4365139813 hasRelatedWork W2153658479 @default.
• W4365139813 hasRelatedWork W2328354663 @default.
• W4365139813 hasRelatedWork W2372642635 @default.
• W4365139813 hasRelatedWork W2376801220 @default.
• W4365139813 hasRelatedWork W2383671142 @default.
• W4365139813 hasRelatedWork W2779222010 @default.
• W4365139813 hasRelatedWork W2890697011 @default.
• W4365139813 hasRelatedWork W3155674270 @default.
• W4365139813 hasRelatedWork W3187572025 @default.
• W4365139813 hasVolume "11" @default.
• W4365139813 isParatext "false" @default.
• W4365139813 isRetracted "false" @default.
• W4365139813 workType "article" @default.